SCHEMBL2969962

SCHEMBL2969962

Cc1ccc(C(=O)Nc2cccc(N(C)C)c2)cc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.59
MAPT P10636 5/20 0.59
ALDH1A1 P00352 3/20 0.59
BRAF P15056 2/20 0.59
KDM4E B2RXH2 2/20 0.59
HPGD P15428 2/20 0.59
RAF1 P04049 1/20 0.59
TP53 P04637 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
ALOX15 P16050 1/20 0.59
MAPK11 Q15759 1/20 0.59
HSD17B10 Q99714 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
KCNK3 O14649 2/20 0.57
SMO Q99835 1/20 0.54
BTK Q06187 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5897054 0.90 MAPK14 (0.65) MAPK14MAPTALDH1A1BRAFKDM4E
SCHEMBL12764301 0.88 MAPK14 (0.62) MAPK14MAPTALDH1A1BRAFKDM4E
SCHEMBL22025458 0.83 MEN1 (0.69) MAPTALDH1A1TP53KCNK3SMN1; SMN2
SCHEMBL22066261 0.83 MAPK14 (0.64) MAPK14MAPTALDH1A1BRAFKDM4E
SCHEMBL7606555 0.82 KCNK3 (0.68) MAPK14MAPTALDH1A1BRAFKDM4E
SCHEMBL6809737 0.82 KMT2A (0.60) MAPTTP53TDP1HDAC6KCNK3
SCHEMBL19070454 0.81 MAPT (0.59) MAPTKDM4ETP53TDP1KCNK3
SCHEMBL22025010 0.81 KCNK3 (0.60) BRAFHPGDKCNK3SMN1; SMN2MEN1
SCHEMBL11315847 0.81 KCNK3 (0.60) MAPTALDH1A1BRAFKDM4EHPGD
SCHEMBL12764313 0.81 KCNK3 (0.80) MAPTTP53CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
WO-2007024754-A1 BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES AMGEN INC. (US) 2007-03-01 WO disclosed
CN-1243724-C Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2006-03-01 CN disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
CN-1330631-A Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2002-01-09 CN disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 MAPK14 1775/4885MAPT 4659/4885ALDH1A1 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.